Inflammation and neurodegenerative diseases.

The decline in mental fitness associated with Alzheimer disease is accompanied by physical changes in the brain, including the development of characteristic plaques and neurofibrillary tangles, but the pathogenesis of those changes is not clear. Recent work suggests that the activation of microglia in response to injury, illness, aging, or other causes begins a cascade of events that can best be characterized as an inflammatory process. This cascade is mediated at first by the proinflammatory cytokine interleukin 1, which is overexpressed by the activated microglia. Through various pathways, interleukin 1 causes neuronal death, which activates more microglia, which in turn release more interleukin 1 in a self-sustaining and self-amplifying fashion. Over a period of years, this slow, smoldering inflammation in the brain destroys sufficient neurons to cause the clinical signs of Alzheimer disease.

[1]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[2]  R. Mrak,et al.  Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation , 2001, Neurochemistry International.

[3]  D Emilie,et al.  In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells. , 1993, Journal of immunology.

[4]  D. Marshak,et al.  Increased S100 beta neurotrophic activity in Alzheimer's disease temporal lobe. , 1992, Neurobiology of aging.

[5]  W. Griffin,et al.  Life-long overexpression of S100β in Down’s syndrome: implications for Alzheimer pathogenesis , 1998, Neurobiology of Aging.

[6]  S. Paul,et al.  Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. , 2000, Journal of neurochemistry.

[7]  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[8]  S. Barger,et al.  S100β Increases Levels of β‐Amyloid Precursor Protein and Its Encoding mRNA in Rat Neuronal Cultures , 1998 .

[9]  D. Graham,et al.  Microglial interleukin-lα expression in human head injury: Correlations with neuronal and neuritic β-amyloid precursor protein expression , 1994, Neuroscience Letters.

[10]  R. Mrak,et al.  Increased Neuronal β‐Amyloid Precursor Protein Expression in Human Temporal Lobe Epilepsy: Association with Interleukin‐1α Immunoreactivity , 1994 .

[11]  D. Marshak,et al.  Increased S100β neurotrophic activity in Alzheimer's disease temporal lobe , 1992, Neurobiology of Aging.

[12]  J. Bauer,et al.  IL-6-mediated events in Alzheimer's disease pathology. , 1991, Immunology today.

[13]  R. Mrak,et al.  Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. , 1994, Journal of neurochemistry.

[14]  D. Graham,et al.  Altered beta-APP metabolism after head injury and its relationship to the aetiology of Alzheimer's disease. , 1996, Acta neurochirurgica. Supplement.

[15]  W. Griffin,et al.  Senescence-Accelerated Overexpression of S100β in Brain of SAMP6 Mice , 1998, Neurobiology of Aging.

[16]  D. Sakas,et al.  Elevated serum S-100B protein as a predictor of failure to short-term return to work or activities after mild head injury. , 2004, Journal of neurotrauma.

[17]  J. Symons,et al.  CORRELATION OF PLASMA INTERLEUKIN 1 LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS , 1988, The Lancet.

[18]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[19]  E. Benveniste,et al.  Induction and regulation of interleukin-6 gene expression in rat astrocytes , 1990, Journal of Neuroimmunology.

[20]  S. Barger,et al.  Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway , 2003, The Journal of Neuroscience.

[21]  S. Barger,et al.  S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons , 2000, Journal of neurochemistry.

[22]  S. Barger,et al.  S100B‐induced microglial and neuronal IL‐1 expression is mediated by cell type‐specific transcription factors , 2005, Journal of neurochemistry.

[23]  D W Dickson,et al.  Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. , 1993, Journal of immunology.

[24]  W. Griffin,et al.  Overexpression of the Neuritotrophic Cytokine S100β Precedes the Appearance of Neuritic β‐Amyloid Plaques in APPV717F Mice , 2000 .

[25]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[26]  R. Mrak,et al.  Human brain S100β and S100β mRNA expression increases with age: Pathogenic implications for Alzheimer's disease , 1996, Neurobiology of Aging.

[27]  W. Griffin,et al.  Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression , 1998, Brain pathology.

[28]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[29]  R. Mrak,et al.  Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. , 1996, Neurobiology of aging.

[30]  M. Piazza,et al.  HEPATITIS B NOT TRANSMISSIBLE VIA FÆCAL-ORAL ROUTE , 1975, The Lancet.

[31]  G. Huber,et al.  Beta-amyloid precursor protein isoforms in various rat brain regions and during brain development. , 1992, Journal of neurochemistry.

[32]  G. Forloni,et al.  Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. , 1992, Brain research. Molecular brain research.

[33]  Gentleman,et al.  Overexpression of S100β in Down’s syndrome: correlation with patient age and with β‐amyloid deposition , 1999 .

[34]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Graham,et al.  Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. , 1994, Neuroscience letters.

[36]  D. Graham,et al.  Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. , 1993, Neuroscience letters.

[37]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Griffin,et al.  Interleukin-1 Promotes Expression and Phosphorylation of Neurofilament and tau Proteins in Vivo , 2000, Experimental Neurology.

[39]  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[40]  H. Braak,et al.  Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat , 1994, Neuroscience Letters.

[41]  S. Paul,et al.  Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. , 2000, Neurology.

[42]  W. Griffin,et al.  Microglial inter leukin‐1α expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution , 1995, Neuropathology and applied neurobiology.

[43]  D. Selkoe,et al.  Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. W. Harris,et al.  Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Graham,et al.  Altered β-APP Metabolism After Head Injury and its Relationship to the Aetiology of Alzheimer’s Disease , 1996 .

[46]  H. Northoff,et al.  Growth control of cultured microglia , 1992, Journal of neuroscience research.

[47]  A. Nebreda,et al.  Reactivating kinase/p38 phosphorylates tau protein in vitro. , 1997, Journal of neurochemistry.

[48]  D. Walker,et al.  Complement and cytokine gene expression in cultured microglia derived from postmortem human brains , 1995, Journal of neuroscience research.

[49]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[50]  S. Barger,et al.  S100 beta increases levels of beta-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. , 1998, Journal of neurochemistry.

[51]  D. Selkoe,et al.  The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. , 1992, Alzheimer disease and associated disorders.

[52]  D. Graham,et al.  β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injury , 1993, Neuroscience Letters.

[53]  R. Skinner,et al.  In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis , 1996, Neurobiology of Aging.

[54]  R. Mrak,et al.  Correlation of Astrocytic S100β Expression with Dystrophic Neurites in Amyloid Plaques of Alzheimer's Disease , 1996, Journal of neuropathology and experimental neurology.

[55]  W. Griffin,et al.  S100β protein expression in Alzheimer disease: Potential role in the pathogenesis of neuritic plaques , 1994 .

[56]  G. Huber,et al.  β‐Amyloid Precursor Protein Isoforms in Various Rat Brain Regions and During Brain Development , 1992 .

[57]  A. Nebreda,et al.  Reactivating Kinase/p38 Phosphorylates τ Protein In Vitro , 1997 .

[58]  R. Zinkernagel,et al.  On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases , 1989, European journal of immunology.

[59]  D. Selkoe,et al.  The Seminal Role of β‐Amyloid in the Pathogenesis of Alzheimer Disease , 1992 .

[60]  E. Giacobini,et al.  Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. , 1995, Neuroreport.

[61]  D. Mann,et al.  Overexpression of s100beta in Down's syndrome: correlation with patient age and with beta-amyloid deposition. , 1999, Neuropathology and applied neurobiology.

[62]  J. Grondin,et al.  Induction of interleukin-6 in axotomized sensory neurons , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[63]  S. Barger,et al.  Microglial activation by uptake of fDNA via a scavenger receptor , 2004, Journal of Neuroimmunology.

[64]  S. Barger,et al.  Neuronal–Glial Interactions Mediated by Interleukin-1 Enhance Neuronal Acetylcholinesterase Activity and mRNA Expression , 2000, The Journal of Neuroscience.

[65]  L. V. Van Eldik,et al.  S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions. , 1994, Biochimica et biophysica acta.

[66]  E. Mufson,et al.  Colocalization of cholinesterases with β amyloid protein in aged and Alzheimer's brains , 2004, Acta Neuropathologica.

[67]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[68]  W. Oertel,et al.  Association of an interleukin 1α polymorphism with Alzheimer’s disease , 2000, Neurology.